Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Hepion Pharmaceuticals, Inc.
Hepion Pharmaceuticals, Inc. News
May 12, 2025 - globenewswire.com
Hepion Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq
May 7, 2025 - globenewswire.com
Hepion Pharmaceuticals Executes Binding Letter of Intent with New Day Diagnostics to Commercialize Diagnostic Tests for Celiac Disease, Respiratory Multiplex, H. Pylori and HCC
Hepion Pharmaceuticals, Inc. Quantitative Score
About Hepion Pharmaceuticals, Inc.
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in clinical-phase development for the treatment of non-alcoholic steatohepatitis (NASH), as well as in nonclinical studies to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH, and has demonstrated antiviral activities towards hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.
Hepion Pharmaceuticals, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Hepion Pharmaceuticals, Inc. Financials
Table Compare
Compare HEPA metrics with: | |||
|---|---|---|---|
Earnings & Growth | HEPA | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | HEPA | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | HEPA | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | HEPA | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Hepion Pharmaceuticals, Inc. Income
Hepion Pharmaceuticals, Inc. Balance Sheet
Hepion Pharmaceuticals, Inc. Cash Flow
Hepion Pharmaceuticals, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Buy |
| Return on Equity | Strong Buy |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Hepion Pharmaceuticals, Inc. Executives
| Name | Role |
|---|---|
| Mr. John Patrick Brancaccio CPA | Interim Chief Executive Officer, Interim Chief Financial Officer & Chairman of the Board |
| Sharen Pyatetskaya | Director of Investor Relations |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. John Patrick Brancaccio CPA | Interim Chief Executive Officer, Interim Chief Financial Officer & Chairman of the Board | Male | 1948 | 376.69K |
| Sharen Pyatetskaya | Director of Investor Relations | -- |
Hepion Pharmaceuticals, Inc. Insider Trades
| Date | 6 Mar |
| Name | Purcell Michael J. |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 50000 |
| Date | 5 Mar |
| Name | Purcell Michael J. |
| Role | Director |
| Transaction | Disposed |
| Type | |
| Shares | 0 |
| Date | 19 Feb |
| Name | Block Timothy M. |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 85000 |
| Date | 19 Feb |
| Name | JACOB GARY S |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 85000 |
| Date | 19 Feb |
| Name | Lbiati Kaouthar |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 85000 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 6 Mar | Purcell Michael J. | Director | Acquired | A-Award | 50000 |
| 5 Mar | Purcell Michael J. | Director | Disposed | 0 | |
| 19 Feb | Block Timothy M. | Director | Acquired | A-Award | 85000 |
| 19 Feb | JACOB GARY S | Director | Acquired | A-Award | 85000 |
| 19 Feb | Lbiati Kaouthar | Director | Acquired | A-Award | 85000 |